Salivary Secretory Immunoglobulin (SIgA) and Lysozyme in Malignant Tumor Patients

Table 5

Analysis of covariance the factors influencing salivary SIgA and lysozyme in cancer patients.

Variables		SIgA (µg/mL)	P value	Lysozyme (ng/mL)	P value
Age
<60	162	24.82 ± 3.96	<0.01	54.26 ± 12.28	0.45
≥60	59	27.54 ± 4.13		52.88 ± 11.27
Gender
Male	142	25.88 ± 4.23	0.13	53.89 ± 11.85	0.86
Female	79	24.95 ± 4.03		53.88 ± 12.36
Active periodontal disease
Yes	9	28.27 ± 6.96	0.27	59.00 ± 8.59	0.21
No	212	25.43 ± 4.00		53.67 ± 12.10
Volume of unstimulated saliva (mL/5 min)
<2 mL	151	25.63 ± 4.00	0.69	53.15 ± 11.70	0.19
≥2 mL	70	25.37 ± 4.63		55.49 ± 12.66
Neutropenia
<1.5 × 10^9	61	22.83 ± 3.31	<0.01	53.80 ± 10.11	0.86
>1.5 × 10^9	160	26.53 ± 3.88		53.92 ± 12.69
Corticoid therapy
Yes	111	24.25 ± 3.98	<0.01	54.06 ± 11.05	0.75
No	110	26.78 ± 3.77		53.72 ± 12.96
Regular chemotherapy
Yes	127	25.45 ± 4.07	0.82	54.00 ± 12.86	0.89
No	94	25.58 ± 4.10		53.74 ± 10.81
Use of drugs with epithelial cells toxicity
Yes	26	21.47 ± 2.18	<0.01	58.09 ± 12.33	0.07
No	195	26.05 ± 3.96		53.33 ± 11.89
Antibacterial drug use ≥ 3 d
Yes	83	23.49 ± 3.76	<0.01	54.99 ± 11.00	0.34
No	138	26.72 ± 3.77		53.28 ± 12.60
Antifungal drug use
Yes	55	22.25 ± 2.68	<0.01	57.57 ± 9.14	<0.01
No	166	26.58 ± 3.88		52.67 ± 12.61
Invasive treatment
Yes	92	23.50 ± 3.97	<0.001	55.21 ± 10.30	0.18
No	129	26.94 ± 3.52		52.95 ± 13.05
Drug mouthwash
Yes	47	22.67 ± 2.52	<0.001	53.85 ± 6.68	0.86
No	174	26.27 ± 4.08		53.90 ± 13.10

Data was analyzed by -test.